- Advanced search
- Immuno Portal
- Malaria Portal
Molecular properties generated using the CDK
|No information available.|
|Summary of Clinical Use|
|Tivozanib was approved by the EMA in 2017, and it is also approved for use in Norway and Iceland. It is not FDA approved. Tivozanib is indicated as a first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC.
Click here to view all tivozanib studies that are currently listed on ClinicalTrials.gov.
A press release from the drug's developer Aveo Oncology, announced that the FDA would not recommend submission of a New Drug Application (NDA) for tivozanib for RCC with the preliminary overall survival results from the Phase 3 TIVO-3 trial (tivozanib vs sorafenib). Aveo is awaiting more mature overall survival results before making any further NDA filing decisions (as of July 2019).
|Mechanism Of Action and Pharmacodynamic Effects|
|Tivozanib selectively inhibits VEGFR activation which suppresses the downstream pro-angiogenic sequelae of VEGF activity at these receptor tyrosine linases.|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)